Literature DB >> 1594020

Breast cancer therapy--the price of success.

I C Henderson.   

Abstract

Entities:  

Mesh：

Year:  1992        PMID： 1594020     DOI： 10.1056/NEJM199206253262611

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  2 in total

1.  Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression.

Authors:  C Wolf; N Rouyer; Y Lutz; C Adida; M Loriot; J P Bellocq; P Chambon; P Basset
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

2.  The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy.

Authors:  P Manders; L V A M Beex; V C G Tjan-Heijnen; J Geurts-Moespot; T H Van Tienoven; J A Foekens; C G J Sweep
Journal:  Br J Cancer       Date:  2002-09-23       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.